{"title":"Biotechnology: Pharmaceutical Aspects","description":null,"products":[{"product_id":"immunogenicity-of-biopharmaceuticals-book-marco-weert-9780387758404","title":"Immunogenicity of Biopharmaceuticals","description":"A particular issue for biopharmaceuticals that has not been addressed comprehensively in any book, is the potential of an immune response to the biopharmaceutical product.","brand":"WoB","offers":[{"title":"- \/ - \/ -","offer_id":50466068496657,"sku":"","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ VERY_GOOD \/ SBYB","offer_id":50466070790417,"sku":"CIN0387758402VG","price":0.0,"currency_code":"GBP","in_stock":false},{"title":"GB \/ NEW \/ INGRAM","offer_id":52660509606161,"sku":"NLS9780387758404","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/0387758402.jpg?v=1750941992"},{"product_id":"examining-the-science-behind-nutraceuticals-book-larry-augsburger-9780971176706","title":"Examining the Science Behind Nutraceuticals","description":"Over half of the adult population in the U.S. includes some sort of dietary supplement in their diet. This book provides the reader with a better understanding of the science and quality issues of dietary supplements. It explains terms regarding supplements, regulatory implications and standards of botanical extracts, and provides background on the supplement industry and pharmacoeconomics of supplements. It also identifies the health benefits and risks.","brand":"WoB","offers":[{"title":"- \/ - \/ -","offer_id":50467320267025,"sku":"","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ GOOD \/ SBYB","offer_id":50467320922385,"sku":"CIN0971176701G","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/0971176701.jpg?v=1751298753"},{"product_id":"methods-for-structural-analysis-of-protein-pharmaceuticals-book-wim-jiskoot-9780971176720","title":"Methods for Structural Analysis of Protein Pharmaceuticals","description":"In addition to serving the analytical chemist, this book is needed by the formulation scientist who is responsible for design and formulation of a pharmaceutical protein that can be monitored during production and over time.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52135383630097,"sku":"NLS9780971176720","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9780971176720.jpg?v=1757548770"},{"product_id":"optimizing-the-drug-like-properties-of-leads-in-drug-discovery-book-ronald-borchardt-9781493950478","title":"Optimizing the \"Drug-Like\" Properties of Leads in Drug Discovery","description":"Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e., discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, drug-like properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52333232029969,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52333233013009,"sku":"NLS9781493950478","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9781493950478.jpg?v=1758154117"},{"product_id":"immunogenicity-of-biopharmaceuticals-book-marco-weert-9781441926081","title":"Immunogenicity of Biopharmaceuticals","description":"Immunogenicity of Biopharmaceuticals is the first book to comprehensively address the potential of an immune response to biopharmaceuticals.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52480763625745,"sku":"NLS9781441926081","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":52953439142161,"sku":"NIN9781441926081","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9781441926081.jpg?v=1759850715"},{"product_id":"advances-in-bioactivation-research-book-adnan-elfarra-9780387772998","title":"Advances in Bioactivation Research","description":"Provides researchers with information on bioactivation reactions of drugs and toxicants. This title contains examples of how molecular and genomic biology, proteomics, mass spectrometry, and computational modeling are used in bioactivation research.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52488120140049,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52488120500497,"sku":"NLS9780387772998","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9780387772998.jpg?v=1759862541"},{"product_id":"drug-absorption-studies-book-carsten-ehrhardt-9781489977540","title":"Drug Absorption Studies","description":"This is a well thought-out, highly practical text covering contemporary 'in vitro' techniques for drug absorption studies. Starting at the molecular level of investigation, it continues with cell monolayer models (both primary and cell lines) and culminates with in situ techniques as a final testing format.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52589056753937,"sku":"NLS9781489977540","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9781489977540.jpg?v=1761059292"},{"product_id":"optimizing-the-drug-like-properties-of-leads-in-drug-discovery-book-ronald-borchardt-9780387340562","title":"Optimizing the \"Drug-Like\" Properties of Leads in Drug Discovery","description":"Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e., discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, drug-like properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52617721643281,"sku":"NLS9780387340562","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9780387340562.jpg?v=1761531141"},{"product_id":"advances-in-bioactivation-research-book-adnan-elfarra-9781493938797","title":"Advances in Bioactivation Research","description":"I have always been interested in chemistry and biology. My undergraduate, graduate, and postdoctoral trainings in pharmacy, medicinal chemistry and pharmacology, respectively, have strengthened this interest and led me to realize that significant advances in medicine have frequently been realized because of research at the chem- try–biology interface. I am hoping that this comprehensive volume on recent advances in bioactivation research will stimulate pharmacologists, medicinal chemists, phar- ceutical scientists, and graduate students in these fields and related areas to consider and use bioactivation research when they explore and chart new frontiers in drug design and drug development and when they consider ways to reduce the side effects of existing drugs by making prodrugs. As for the toxicologists and environmental health scientists, I hope this volume will help them generate the knowledge needed to understand better mechanisms of toxicity to improve human risk assessments and intervention methods after occupational or environmental exposure to various hazardous chemicals. Adnan A. Elfarra, Ph. D. vii Part I General Concepts and Basic Mechanisms 1 Metabolic Concerns in Drug Design Jeffrey P. Jones Department of Chemistry, Washington State University, Pullman, WA 99164, USA e-mail: jpj@wsu. edu Keywords: Cytochrome P450 Aldehyde Oxidase Drug–Drug Interactions  Mechanism-based Virtual Screening ADMET Regioselectivity  1. 1. Introduction Due to recent technological innovations, such as genomics, combinatorial chemistry, and high-throughput screening, the identification of disease targets and of compounds that are active against these targets (‘‘leads’’) can now be carried out efficiently.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52650403365137,"sku":"NLS9781493938797","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9781493938797.jpg?v=1762127878"},{"product_id":"current-trends-in-monoclonal-antibody-development-and-manufacturing-book-steven-j-shire-9781461424918","title":"Current Trends in Monoclonal Antibody Development and Manufacturing","description":"Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade.   Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. Current Trends in Monoclonal Antibody Development and Manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52664684511505,"sku":"NLS9781461424918","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9781461424918.jpg?v=1762275268"},{"product_id":"solvent-systems-and-their-selection-in-pharmaceutics-and-biopharmaceutics-book-patrick-augustijns-9780387691497","title":"Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics","description":"Solvent systems are integral to drug development and pharmaceutical technology. This single topic encompasses numerous allied subjects running the gamut from recrystallization solvents to biorelevant media. The goal of this contribution to the AAPS Biotechnology: Pharmaceutical Aspects series is to generate both a practical handbook as well as a reference allowing the reader to make effective decisions concerning the use of solvents and solvent systems. To this end, the monograph was created by inviting recognized experts from a number of fields to author relevant sections. Specifically, 15 chapters have been designed covering the theoretical background of solubility, the effect of ionic equilibria and pH on solubilization, the use of solvents to effect drug substance crystallization and polymorph selection, the use of solvent systems in high throughput screening and early discovery, solvent use in preformulation, the use of solvents in bio-relevant dissolution and permeation experiments, solvents and their use as toxicology vehicles, solubilizing media and excipients in oral and parenteral formulation development, specialized vehicles for protein formulation and solvent systems for topical and pulmonary drug administration. The chapters are organized such that useful decision trees are included together with the scientific underpinning for their application. In addition, trends in the use of solvent systems and a balance of current views make this monograph useful to both the novice and experienced researcher and to scientists at all developmental stages from early discovery to late pharmaceutical operations.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52666273825041,"sku":"NLS9780387691497","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":52735225200913,"sku":"NIN9780387691497","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9780387691497.jpg?v=1762279529"},{"product_id":"nanotechnology-in-drug-delivery-book-melgardt-m-de-villiers-9780387776675","title":"Nanotechnology in Drug Delivery","description":"The reader will be introduced to various aspects of the fundamentals of nanotechnology based drug delivery systems and the application of these systems for the delivery of small molecules, proteins, peptides, oligonucleotides and genes. How these systems overcome challenges offered by biological barriers to drug absorption and drug targeting will also be described.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52676007919889,"sku":"NLS9780387776675","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9780387776675.jpg?v=1762303261"},{"product_id":"current-trends-in-monoclonal-antibody-development-and-manufacturing-book-steven-j-shire-9780387766423","title":"Current Trends in Monoclonal Antibody Development and Manufacturing","description":"Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade.   Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. Current Trends in Monoclonal Antibody Development and Manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52677539987729,"sku":"NLS9780387766423","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9780387766423.jpg?v=1762306225"},{"product_id":"pharmaceutical-stability-testing-to-support-global-markets-book-kim-huynh-ba-9781461425366","title":"Pharmaceutical Stability Testing to Support Global Markets","description":"The International Conference of Harmonization (ICH) has worked on har- nizing the stability regulations in the US, Europe, and Japan since the early 1990s. Even though the Stability Guidelines Q1A (R2) was issued over a decade ago, issues surrounding this arena continue to surface as the principles described in the guideline are applied to different technical concentrations. As a result, the stability community has continued to discuss concerns and find ways of harmonizing regulatory requirements, streamlining practices, improving processes in order to bring safe and effective medical supplies to the patients around the world. In 2007, the American Association of Pharmaceutical Scientists (AAPS) Stability Focus Group organized two workshops - the Stability Workshop and the Degradation Mechanism Workshop. These meetings attracted many industry scientists as well as representatives from several regulatory agencies in the world to discuss important topics related to pharmaceutical stability practices. Recognizing the importance of documenting these discussions and with the permission of AAPS, I have worked with speakers to assemble a collection of 30 articles from presentations given at these two meetings, mainly the Stability Workshop. I trust that this book will be beneficial to all of you in providing guidance and up-to-date information for building quality stability programs. v Freedom of our mind is Mother of all inventions.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52678538428689,"sku":"NLS9781461425366","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9781461425366.jpg?v=1762308361"},{"product_id":"drug-absorption-studies-book-carsten-ehrhardt-9780387749006","title":"Drug Absorption Studies","description":"This is a well thought-out, highly practical text covering contemporary 'in vitro' techniques for drug absorption studies. It will be essential reading for any number of professionals in drug research. What's more, an appendix consisting of a number of practical protocols is available online.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52678885572881,"sku":"NLS9780387749006","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9780387749006.jpg?v=1762309235"},{"product_id":"pharmaceutical-stability-testing-to-support-global-markets-book-kim-huynh-ba-9781441908889","title":"Pharmaceutical Stability Testing to Support Global Markets","description":"The International Conference of Harmonization (ICH) has worked on har- nizing the stability regulations in the US, Europe, and Japan since the early 1990s. Even though the Stability Guidelines Q1A (R2) was issued over a decade ago, issues surrounding this arena continue to surface as the principles described in the guideline are applied to different technical concentrations. As a result, the stability community has continued to discuss concerns and find ways of harmonizing regulatory requirements, streamlining practices, improving processes in order to bring safe and effective medical supplies to the patients around the world. In 2007, the American Association of Pharmaceutical Scientists (AAPS) Stability Focus Group organized two workshops - the Stability Workshop and the Degradation Mechanism Workshop. These meetings attracted many industry scientists as well as representatives from several regulatory agencies in the world to discuss important topics related to pharmaceutical stability practices. Recognizing the importance of documenting these discussions and with the permission of AAPS, I have worked with speakers to assemble a collection of 30 articles from presentations given at these two meetings, mainly the Stability Workshop. I trust that this book will be beneficial to all of you in providing guidance and up-to-date information for building quality stability programs. v Freedom of our mind is Mother of all inventions.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52680754790673,"sku":"NLS9781441908889","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":53009819959569,"sku":"NIN9781441908889","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9781441908889.jpg?v=1762313905"}],"url":"https:\/\/www.worldofbooks.com\/en-ie\/collections\/biotechnology-pharmaceutical-aspects-book-series.oembed","provider":"World of Books ","version":"1.0","type":"link"}